Shares of Astrana Health, Inc. (NASDAQ:ASTH – Get Free Report) have received an average rating of “Moderate Buy” from the ten ratings firms that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $49.88.
ASTH has been the subject of several research analyst reports. Wall Street Zen cut Astrana Health from a “buy” rating to a “hold” rating in a research report on Sunday, August 16th. BTIG Research boosted their price target on shares of Astrana Health from $50.00 to $65.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Truist Financial boosted their target price on Astrana Health from $47.00 to $55.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Oppenheimer started coverage on Astrana Health in a research note on Tuesday, September 15th. They set an “outperform” rating and a $53.00 price target for the company. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Astrana Health in a report on Thursday, August 27th.
Read Our Latest Analysis on Astrana Health
Institutional Trading of Astrana Health
Astrana Health Stock Down 0.4%
ASTH opened at $37.72 on Thursday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.23 and a current ratio of 1.23. Astrana Health has a fifty-two week low of $18.08 and a fifty-two week high of $51.60. The firm’s fifty day moving average is $37.18 and its 200 day moving average is $37.44. The stock has a market cap of $2.10 billion, a price-to-earnings ratio of 46.00 and a beta of 1.03.
Astrana Health (NASDAQ:ASTH – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.46. Astrana Health had a net margin of 1.05% and a return on equity of 10.30%. The company had revenue of $972.52 million during the quarter, compared to the consensus estimate of $985.62 million. During the same quarter in the prior year, the firm posted $0.19 EPS. Astrana Health’s quarterly revenue was up 48.5% compared to the same quarter last year. On average, sell-side analysts forecast that Astrana Health will post 1.36 earnings per share for the current fiscal year.
Astrana Health Company Profile
Astrana Health, Inc is a healthcare enablement company that helps physicians and other healthcare providers deliver coordinated, value-based care. The company works with medical groups, independent physician associations and healthcare organizations to manage patient populations, improve clinical outcomes and coordinate services across primary, specialty and post-acute care settings.
Astrana Health provides care-management programs, population-health analytics, technology solutions and administrative support designed to help providers manage risk-based reimbursement arrangements.
Featured Articles
- Five stocks we like better than Astrana Health
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter.
